Increased plasma levels of interleukin-6 in sepsis [see comments]
暂无分享,去创建一个
L. G. Thijs | L. A. Aarden | C. Hack | L. Thijs | J. Nuijens | L. Aarden | R. Felt‐Bersma | A. Eerenberg-Belmer | E. D. Groot | R. J. Schijndel | C. E. Hack | Er De Groot | Rj Felt-Bersma | J. H. Nuijens | R. J. M. Strack van Schijndel | A. J. M. Eerenberg-Belmer | L. Aarden | E. D. de Groot | C. Hack | CE Hack | ER De Groot | JH Nuijens | RJ Strack Van Schijndel | AJ Eerenberg-Belmer | LG Thijs | LA Aarden | JH Nuijens | RJ Strack Van Schijndel | AJ Eerenberg-Belmer | LG. Thijs | J. Nuijens | Aj Eerenberg-Belmer | LG Thijs
[1] J. D. Albert,et al. Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.
[2] W. R. Mccabe. Serum complement levels in bacteremia due to gram-negative organisms. , 1973, The New England journal of medicine.
[3] R. Cotran,et al. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells , 1984, The Journal of experimental medicine.
[4] S. Tatter,et al. Multiple forms of IFN-beta 2/IL-6 in serum and body fluids during acute bacterial infection. , 1989, Journal of immunology.
[5] C. Hack,et al. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. , 1989, The American journal of medicine.
[6] D. Belin,et al. Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors , 1986, The Journal of experimental medicine.
[7] A. Groeneveld,et al. Hemodynamic determinants of mortality in human septic shock. , 1986, Surgery.
[8] T. Raffin,et al. Tumor necrosis factor causes increased pulmonary permeability and edema. Comparison to septic acute lung injury. , 1988, The American review of respiratory disease.
[9] T. Hirano,et al. Induction of rat acute‐phase proteins by interleukin 6 in vivo , 1988, European journal of immunology.
[10] L. Aarden,et al. Interleukin 6 (IL-6) in serum and urine of renal transplant recipients. , 1988, Clinical and experimental immunology.
[11] A. Cerami,et al. Detection of circulating tumor necrosis factor after endotoxin administration. , 1988, The New England journal of medicine.
[12] L. Aarden,et al. Functional discrimination between interleukin 6 and interleukin 1 , 1988, European journal of immunology.
[13] T. Taniguchi,et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin , 1986, Nature.
[14] B. Hazenberg,et al. The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. , 1988, Biochemical and biophysical research communications.
[15] S. Clark,et al. B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes. , 1988, Journal of immunology.
[16] R. Ulevitch,et al. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. , 1988, The Journal of clinical investigation.
[17] C. Uyttenhove,et al. Interleukin‐HP1‐related hybridoma and plasmacytoma growth factors induced by lipopolysaccharide in vivo , 1987, European journal of immunology.
[18] D. Stern,et al. Modulation of endothelial cell hemostatic properties by tumor necrosis factor , 1986, The Journal of experimental medicine.
[19] F. Houssiau,et al. Elevated levels of the 26K human hybridoma growth factor (interleukin 6) in cerebrospinal fluid of patients with acute infection of the central nervous system. , 1988, Clinical and experimental immunology.
[20] T. Ikejima,et al. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. , 1988, The Journal of clinical investigation.
[21] H. Baumann,et al. Synthesis of hemopexin and cysteine protease inhibitor is coordinately regulated by HSF-II and interferon-beta 2 in rat hepatoma cells. , 1987, Biochemical and biophysical research communications.
[22] P. Lansdorp,et al. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[23] P. Brandtzaeg,et al. Brief Definitive Report the Complex Pattern of Cytokines in Serum from Patients with Meningococcal Septic Shock Association between Interleukin 6, Interleukin 1, and Fatal Outcome , 2022 .
[24] B. Beutler,et al. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.
[25] A. Waage,et al. ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASE , 1987, The Lancet.
[26] L. Aarden,et al. Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases. , 1988, Scandinavian journal of rheumatology.
[27] J H Korn,et al. Structure and expression of cDNA and genes for human interferon‐beta‐2, a distinct species inducible by growth‐stimulatory cytokines. , 1986, The EMBO journal.
[28] A. Waage,et al. Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice , 1988, The Journal of experimental medicine.
[29] Kevin J. Tracey,et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.
[30] W. Fiers,et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[31] B. Beutler,et al. Cachectin: more than a tumor necrosis factor. , 1987, The New England journal of medicine.
[32] W. Vogt. Anaphylatoxins: possible roles in disease. , 1986, Complement.
[33] G. Opdenakker,et al. Induction of a 26-kDa-protein mRNA in human cells treated with an interleukin-1-related, leukocyte-derived factor. , 1985, European journal of biochemistry.
[34] B. Beutler,et al. The role of cachectin/TNF in endotoxic shock and cachexia. , 1988, Immunology today.
[35] F. Houssiau,et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. , 1988, Arthritis and rheumatism.
[36] G. Opdenakker,et al. Interleukin 1 and poly(rI) · poly(rC) induce production of a hybridoma growth factor by human fibroblasts , 1987, European journal of immunology.
[37] L. Aarden,et al. Interleukin 6 is involved in interleukin 1‐induced activities , 1988, European journal of immunology.